Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as CS3007 (BLU-285)
CS3007 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| CS3007(BLU-285) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| CS3007 (BLU-285) | DRUG | A modified "3+3" dose escalation design will be adopted. Each group will enroll 3-6 subjects. Avapritinib will be administered orally at the starting of 200 mg QD. A cycle consists of 28 consecutive days. |
Inclusion criteria: 1. For phase I study, the subject must have histologically or cytologically confirmed unresectable or metastatic GIST that progressed after imatinib and at least one additional TKI treatment, or who cannot tolerate the standard treatment or have D842V mutation in the PDGFRα gene...
CS3007 is being developed for the treatment of gastrointestinal stromal tumors, a type of cancer affecting the digestive tract. It is an investigational small molecule therapy being studied in patients with this condition. The clinical program has focused on evaluating the drug in adults with gastrointestinal stromal tumors.
CS3007 is being developed by Blueprint Medicines Corporation, which trades on the Nasdaq under the ticker symbol BPMC. The company is responsible for the clinical development of the drug, including the Phase 1 study conducted in China.
CS3007 is in Phase 1 clinical development. The only reported trial for this drug was a Phase 1 study that has been completed. It is an investigational therapy and has not been approved for any indication.
CS3007 has been evaluated in a single Phase 1 clinical trial, NCT04254939, titled A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor. The trial enrolled 65 participants, was conducted in China, and is now completed.
Yes, CS3007 is also known as BLU-285. Both names refer to the same investigational small molecule developed by Blueprint Medicines Corporation for gastrointestinal stromal tumors.